Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View expanded data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View expanded data table
# of AnimalsPhenotypeStrainSexValueUnitsConditionsRecord ID
6plasma albumin levelF344/Jclmale0.38g/lfasting (for 16 hours)76927fasting (for 16 hours)
6plasma triglyceride levelF344/Jclmale0.9605mmol/lfasting (for 16 hours)76933fasting (for 16 hours)
6blood hemoglobin levelF344/Jclmale16.4g/dlfasting (for 16 hours)76914fasting (for 16 hours)
6lung wet weightF344/Jclmale0.744gspecific pathogen-free condition71589specific pathogen-free condition
6spleen weight to body weight ratioF344/Jclmale0.221%specific pathogen-free condition71598specific pathogen-free condition
6mean corpuscular volumeF344/Jclmale63.1flfasting (for 16 hours)76916fasting (for 16 hours)
6body temperatureF344/Jclmale37.7degrees Cspecific pathogen-free condition74942specific pathogen-free condition
6both kidneys wet weight as percentage of body weightF344/Jclmale0.647%specific pathogen-free condition71594specific pathogen-free condition
6hematocritF344/Jclmale55.2%fasting (for 16 hours)76915fasting (for 16 hours)
6brain weight to body weight ratioF344/Jclmale0.943%specific pathogen-free condition71586specific pathogen-free condition
6liver weight as percentage of body weightF344/Jclmale3.003%specific pathogen-free condition71592specific pathogen-free condition
6systolic blood pressureF344/Jclmale136mmHgspecific pathogen-free condition74940specific pathogen-free condition
6lung weight to body weight ratioF344/Jclmale0.396%specific pathogen-free condition71590specific pathogen-free condition
6liver wet weightF344/Jclmale5.647gspecific pathogen-free condition71591specific pathogen-free condition
8liver wet weightF344/Jclmale12.7gcontrol condition13304control condition
6plasma creatinine levelF344/Jclmale0.26mg/dlfasting (for 16 hours)76936fasting (for 16 hours)
6plasma total cholesterol levelF344/Jclmale48mg/dlfasting (for 16 hours)76930fasting (for 16 hours)
6both adrenal glands wet weightF344/Jclmale39.6mgspecific pathogen-free condition71595specific pathogen-free condition
6plasma glucose levelF344/Jclmale167mg/dlfasting (for 16 hours)76929fasting (for 16 hours)
6heart rateF344/Jclmale462beats/minspecific pathogen-free condition74941specific pathogen-free condition
6brain wet weightF344/Jclmale1.768gspecific pathogen-free condition71585specific pathogen-free condition
6mean corpuscular hemoglobin concentrationF344/Jclmale29.8g/dlfasting (for 16 hours)76918fasting (for 16 hours)
6heart wet weightF344/Jclmale0.644gspecific pathogen-free condition71587specific pathogen-free condition
6both kidneys wet weightF344/Jclmale1.216gspecific pathogen-free condition71593specific pathogen-free condition
8body weightF344/Jclmale350.7gcontrol condition13302control condition
6mean corpuscular hemoglobin levelF344/Jclmale18.8pgfasting (for 16 hours)76917fasting (for 16 hours)
6plasma high density lipoprotein cholesterol levelF344/Jclmale30.8mg/dlfasting (for 16 hours)76931fasting (for 16 hours)
6both testes wet weightF344/Jclmale2.633gspecific pathogen-free condition71599specific pathogen-free condition
8both testes wet weightF344/Jclmale6.62gcontrol condition65821control condition
8prostate gland wet weightF344/Jclmale0.92gcontrol condition65832control condition
6plasma low density lipoprotein cholesterol levelF344/Jclmale4mg/dlfasting (for 16 hours)76932fasting (for 16 hours)
8percentage of study population developing ventral prostate tumorous lesions during a period of timeF344/Jclmale50%control condition65824control condition
8ventral prostate gland wet weightF344/Jclmale0.27gcontrol condition65827control condition
6both testes wet weight to body weight ratioF344/Jclmale1.402%specific pathogen-free condition71600specific pathogen-free condition
8prostate tumorous lesion numberF344/Jclmale1.5control condition65823control condition
8area of ventral prostate occupied by tumorous lesions to total ventral prostate area ratioF344/Jclmale0.25%control condition67947control condition
6spleen wet weightF344/Jclmale0.415gspecific pathogen-free condition71597specific pathogen-free condition
8spleen wet weightF344/Jclmale2.34gcontrol condition13306control condition
8area of individual prostate tumorous lesionF344/Jclmale0.22mm2control condition65839control condition
6both adrenal glands weight to body weight ratioF344/Jclmale21mg/100gspecific pathogen-free condition71596specific pathogen-free condition
6body weightF344/Jclmale198.6gspecific pathogen-free condition70688specific pathogen-free condition
6body weightF344/Jclmale94.4gspecific pathogen-free condition70687specific pathogen-free condition
6body weightF344/Jclmale62gspecific pathogen-free condition70686specific pathogen-free condition
8percentage of study population developing testis tumors during a period of timeF344/Jclmale100%control condition65841control condition
8percentage of study population developing bilateral testis tumors during a period of timeF344/Jclmale88%control condition67949control condition
8percentage of study population developing unilateral renal agenesis during a period of timeF344/Jclmale0%control condition106884control condition
8percentage of study population developing leukemia during a period of timeF344/Jclmale25%control condition66142control condition
6plasma urea nitrogen levelF344/Jclmale7.1043mmol/lfasting (for 16 hours)76935fasting (for 16 hours)
6plasma total protein levelF344/Jclmale62mg/mlfasting (for 16 hours)76926fasting (for 16 hours)
6blood basophil count to total leukocyte count ratioF344/Jclmale0%fasting (for 16 hours)76942fasting (for 16 hours)
6plasma phosphate levelF344/Jclmale8.5mg/dlfasting (for 16 hours)76937fasting (for 16 hours)
6activated partial thromboplastin timeF344/Jclmale14.9sfasting (for 16 hours)76922fasting (for 16 hours)
6prothrombin timeF344/Jclmale16.8sfasting (for 16 hours)76921fasting (for 16 hours)
6blood eosinophil count to total leukocyte count ratioF344/Jclmale1%fasting (for 16 hours)76943fasting (for 16 hours)
6blood lymphocyte count to total leukocyte count ratioF344/Jclmale73%fasting (for 16 hours)76946fasting (for 16 hours)
6blood monocyte count to total leukocyte count ratioF344/Jclmale0%fasting (for 16 hours)76947fasting (for 16 hours)
6total plasma calcium levelF344/Jclmale10.5mg/dlfasting (for 16 hours)76938fasting (for 16 hours)
6plasma alkaline phosphatase activity levelF344/Jclmale564IU/lfasting (for 16 hours)76925fasting (for 16 hours)
6urine chloride levelF344/Jclmale164mEq/L0.9% sodium chloride solution (25 ml/kg) 948820.9% sodium chloride solution (25 ml/kg)
6urine potassium excretion rate to body weight ratioF344/Jclmale239uEq/100g/6 hrs0.9% sodium chloride solution (25 ml/kg) 948810.9% sodium chloride solution (25 ml/kg)
6urine chloride excretion rate to body weight ratioF344/Jclmale382uEq/100g/6 hrs0.9% sodium chloride solution (25 ml/kg) 948830.9% sodium chloride solution (25 ml/kg)
6red blood cell countF344/Jclmale0.878x 10E6 cells/ulfasting (for 16 hours)76913fasting (for 16 hours)
6white blood cell countF344/Jclmale3.7x 1000 cells/ulfasting (for 16 hours)76919fasting (for 16 hours)
6platelet countF344/Jclmale761x 1000 cells/ulfasting (for 16 hours)76920fasting (for 16 hours)
6total plasma bilirubin levelF344/Jclmale0.01mg/dlfasting (for 16 hours)76934fasting (for 16 hours)
6plasma sodium levelF344/Jclmale145.4mmol/lfasting (for 16 hours)76939fasting (for 16 hours)
6plasma potassium levelF344/Jclmale4.49mmol/lfasting (for 16 hours)76940fasting (for 16 hours)
6plasma chloride levelF344/Jclmale106mmol/lfasting (for 16 hours)76941fasting (for 16 hours)
6plasma aspartate aminotransferase activity levelF344/Jclmale77U/lfasting (for 16 hours)76923fasting (for 16 hours)
6plasma alanine aminotransferase activity levelF344/Jclmale39U/lfasting (for 16 hours)76924fasting (for 16 hours)
6urine potassium levelF344/Jclmale102.1mmol/l0.9% sodium chloride solution (25 ml/kg) 948800.9% sodium chloride solution (25 ml/kg)
6urine sodium levelF344/Jclmale143.2mmol/l0.9% sodium chloride solution (25 ml/kg) 948780.9% sodium chloride solution (25 ml/kg)
6timed urine volumeF344/Jclmale18.88ml/d0.9% sodium chloride solution (25 ml/kg) 948760.9% sodium chloride solution (25 ml/kg)
6urine sodium excretion rate to body weight ratioF344/Jclmale0.00938uEq/min/g0.9% sodium chloride solution (25 ml/kg) 948790.9% sodium chloride solution (25 ml/kg)
6timed urine volume to body weight ratioF344/Jclmale0.0672ul/min/g0.9% sodium chloride solution (25 ml/kg) 948770.9% sodium chloride solution (25 ml/kg)
6blood segmented neutrophil count to total leukocyte count ratioF344/Jclmale26%fasting (for 16 hours)76945fasting (for 16 hours)
6plasma albumin to plasma total protein ratioF344/Jclmale1.53fasting (for 16 hours)76928fasting (for 16 hours)
6non-specified leukocyte count to total leukocyte count ratioF344/Jclmale0%fasting (for 16 hours)76948fasting (for 16 hours)
6blood band neutrophil count to total leukocyte count ratioF344/Jclmale0%fasting (for 16 hours)76944fasting (for 16 hours)
6heart weight to body weight ratioF344/Jclmale3.43g/kgspecific pathogen-free condition71588specific pathogen-free condition
8percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of timeF344/Jclmale25%control condition109886control condition
8number of ventral prostate tumorous lesions with solid structureF344/Jclmale0.4control condition109888control condition
8area of individual ventral prostate tumorous lesion with a solid structureF344/Jclmale0.06mm2control condition109890control condition
8area of ventral prostate occupied by tumorous lesions with solid structure to total ventral prostate area ratioF344/Jclmale0.07%control condition109892control condition
8percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of timeF344/Jclmale38%control condition109958control condition
8number of ventral prostate tumorous lesions with round, irregular size nucleiF344/Jclmale1.3control condition109960control condition
8area of individual ventral prostate tumorous lesion with round, irregular size nucleiF344/Jclmale0.22mm2control condition109962control condition
8area of ventral prostate occupied by tumorous lesions with round, irregular size nuclei to total ventral prostate area ratioF344/Jclmale0.24%control condition109964control condition
8percentage of study population developing subcutaneous tumors during a period of timeF344/Jclmale38%control condition106886control condition